View Cancer Clinical Trials

Details

Title MORAb-003-011, A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer

IRB MORAb-003-011

CC 15-298

Hospital Fairview, Hillcrest, Main Campus

Stage Recurrent/Relapsed

Phase Phase 2

Disease Fallopian Tube, Gynecologic, Ovarian, Peritoneal

Drug Carboplatin, Doxorubicin, Farletuzumab, Paclitaxel

Description

Trial Description Not Available

Inclusion Criteria

Inclusion Criteria Not Available

Exclusion Criteria

Exclusion Criteria Not Available